{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:28Z","timestamp":1793119408947,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":917,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1093\/annonc\/mdx049","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T20:14:39Z","timestamp":1487276079000},"page":"996-1004","source":"Crossref","is-referenced-by-count":93,"title":["A phase 2, randomized, double-blind, placebo-\u00a0controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study"],"prefix":"10.1016","volume":"28","author":[{"given":"B.J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rizack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kolevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Swisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.S.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Newkirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.L.","family":"Manjarrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.M.","family":"Hershberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx049_bb0010","unstructured":"American Cancer Society. What are the key statistics about ovarian cancer? [article on internet] 2016. https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/about\/key-statistics.html (22 September 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx049_bb0015","unstructured":"NIH National Cancer Institute. SEER Stat Fact Sheets: Ovarian Cancer [database on internet] 2016. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html (9 November 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdx049_bb0020","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","article-title":"Latest research and treatment of advanced-stage epithelial ovarian cancer","volume":"10","author":"Coleman","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.6004\/jnccn.2016.0122","article-title":"Ovarian cancer, Version 1.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Morgan","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1093\/annonc\/mdx049_bb0030","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1038\/sj.bjc.6601787","volume":"90","author":"Buda","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx049_bb0035","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/IGC.0b013e3181daaf59","article-title":"Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdx049_bb0040","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0045","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0050","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2009.25.4037","article-title":"Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0055","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx049_bb0065","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx049_bb0070","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx049_bb0075","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdx049_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx049_bb0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdx049_bb0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1093\/annonc\/mdx049_bb0095","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-11-1625","article-title":"VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC","volume":"18","author":"Lu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx049_bb0100","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-15-0578","article-title":"Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)","volume":"21","author":"Dietsch","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx049_bb0105","article-title":"Integrative development of a TLR8 agonist for ovarian cancer chemo-immunotherapy","author":"Monk","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx049_bb0110","doi-asserted-by":"crossref","first-page":"e0148764.","DOI":"10.1371\/journal.pone.0148764","article-title":"Coordinated activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity","volume":"11","author":"Dietsch","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdx049_bb0115","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00262-013-1437-3","article-title":"TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells","volume":"62","author":"Stephenson","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"suppl 4","key":"10.1093\/annonc\/mdx049_bb0120","first-page":"iv361","article-title":"Adaptation of the immune related response criteria: irRECIST","volume":"25","author":"Bohnsack","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0125","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NIH publication # 09\u20137473. 2009."},{"key":"10.1093\/annonc\/mdx049_bb0130","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdx049_bb0135","article-title":"Immune checkpoint inhibitors: a new opportunity in the treatment of ovarian cancer?","volume":"17","author":"Mittica","year":"2016","journal-title":"IJMS"},{"key":"10.1093\/annonc\/mdx049_bb0140","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.2015.63.7785","article-title":"Targeting programmed cell death 1 in ovarian cancer","volume":"33","author":"Homicsko","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx049_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419320228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/5\/996\/24169403\/mdx049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:15:48Z","timestamp":1624695348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419320228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0923753419320228"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx049","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}